AR121566A1 - Una terapia de combinación con nirogacestat y una terapia dirigida por bcma y usos de las mismas - Google Patents
Una terapia de combinación con nirogacestat y una terapia dirigida por bcma y usos de las mismasInfo
- Publication number
- AR121566A1 AR121566A1 ARP210100641A ARP210100641A AR121566A1 AR 121566 A1 AR121566 A1 AR 121566A1 AR P210100641 A ARP210100641 A AR P210100641A AR P210100641 A ARP210100641 A AR P210100641A AR 121566 A1 AR121566 A1 AR 121566A1
- Authority
- AR
- Argentina
- Prior art keywords
- nirogacestat
- therapy
- bcma
- combination therapy
- subject
- Prior art date
Links
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 229950001637 nirogacestat Drugs 0.000 title abstract 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 title 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- LXEYYZYDWLAIPW-KBVFCZPLSA-N (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide dihydrobromide Chemical group Br.Br.CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C LXEYYZYDWLAIPW-KBVFCZPLSA-N 0.000 abstract 1
- 208000023761 AL amyloidosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000011748 cell maturation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002626 targeted therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989372P | 2020-03-13 | 2020-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121566A1 true AR121566A1 (es) | 2022-06-15 |
Family
ID=75396879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100641A AR121566A1 (es) | 2020-03-13 | 2021-03-12 | Una terapia de combinación con nirogacestat y una terapia dirigida por bcma y usos de las mismas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230121547A1 (OSRAM) |
| EP (1) | EP4132515A1 (OSRAM) |
| JP (2) | JP7781764B2 (OSRAM) |
| KR (1) | KR20230009873A (OSRAM) |
| CN (1) | CN115916188A (OSRAM) |
| AR (1) | AR121566A1 (OSRAM) |
| AU (1) | AU2021236340A1 (OSRAM) |
| BR (1) | BR112022018251A2 (OSRAM) |
| CA (1) | CA3171267A1 (OSRAM) |
| CL (1) | CL2022002479A1 (OSRAM) |
| CO (1) | CO2022014388A2 (OSRAM) |
| IL (1) | IL296075A (OSRAM) |
| MX (1) | MX2022011258A (OSRAM) |
| PE (1) | PE20230614A1 (OSRAM) |
| TW (1) | TW202200132A (OSRAM) |
| WO (1) | WO2021183934A1 (OSRAM) |
| ZA (1) | ZA202209989B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI905452B (zh) | 2021-09-01 | 2025-11-21 | 美商斯普林渥克斯治療有限公司 | 尼羅司他（ｎｉｒｏｇａｃｅｓｔａｔ）之合成 |
| WO2023064872A1 (en) * | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| CN118338900A (zh) * | 2021-11-05 | 2024-07-12 | 斯普林渥克斯治疗有限公司 | 含尼罗加司他的组合物和治疗 |
| CA3239013A1 (en) * | 2021-11-23 | 2023-06-01 | Anantha Rajmohan MUTHUSAMY | Solid state forms of nirogacestat salts |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| CN119486713A (zh) | 2022-05-20 | 2025-02-18 | 斯普林渥克斯治疗有限公司 | 尼罗加司他治疗 |
| EP4678635A1 (en) * | 2023-03-09 | 2026-01-14 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of nirogacestat dihydrobromate, and preparation method therefor and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120065A1 (en) * | 2014-02-05 | 2015-08-13 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides |
| EP3662909A1 (en) * | 2015-07-24 | 2020-06-10 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| JP2020507605A (ja) * | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| US20200055948A1 (en) * | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN110622566B (zh) | 2017-05-05 | 2021-04-20 | 华为技术有限公司 | 一种辅助数据传输方法、设备及系统 |
| EP3706754A1 (en) * | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
| US20210069194A1 (en) * | 2018-01-17 | 2021-03-11 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| CA3101340A1 (en) * | 2018-05-24 | 2019-11-28 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof |
| AU2019277029C1 (en) * | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| KR102923588B1 (ko) * | 2019-04-10 | 2026-02-05 | 스프링웍스 테라퓨틱스, 인크. | 항 bcma 항체 및 감마 세크레타제 억제제의 조합 요법 |
| EP4010322B1 (en) * | 2019-08-09 | 2025-11-05 | Pfizer Inc. | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
-
2021
- 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
- 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
- 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
- 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
- 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
- 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
- 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en not_active Ceased
- 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
- 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
- 2021-03-12 JP JP2022554833A patent/JP7781764B2/ja active Active
- 2021-03-12 EP EP21716907.7A patent/EP4132515A1/en active Pending
- 2021-03-12 IL IL296075A patent/IL296075A/en unknown
- 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Pending
- 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
-
2022
- 2022-09-07 ZA ZA2022/09989A patent/ZA202209989B/en unknown
- 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
- 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
-
2025
- 2025-08-25 JP JP2025139609A patent/JP2025168430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021183934A1 (en) | 2021-09-16 |
| JP7781764B2 (ja) | 2025-12-08 |
| CA3171267A1 (en) | 2021-09-16 |
| BR112022018251A2 (pt) | 2022-11-08 |
| US20230121547A1 (en) | 2023-04-20 |
| IL296075A (en) | 2022-11-01 |
| ZA202209989B (en) | 2025-12-17 |
| AU2021236340A1 (en) | 2022-09-29 |
| JP2023517243A (ja) | 2023-04-24 |
| EP4132515A1 (en) | 2023-02-15 |
| CO2022014388A2 (es) | 2023-02-16 |
| JP2025168430A (ja) | 2025-11-07 |
| TW202200132A (zh) | 2022-01-01 |
| CN115916188A (zh) | 2023-04-04 |
| CL2022002479A1 (es) | 2023-08-18 |
| MX2022011258A (es) | 2023-01-11 |
| KR20230009873A (ko) | 2023-01-17 |
| PE20230614A1 (es) | 2023-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014388A2 (es) | Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| CL2025002208A1 (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas | |
| CR20250458A (es) | Composiciones para inducir la hidrólisis de ras gtp y sus usos | |
| CL2024000201A1 (es) | Composiciones y métodos para la inhibición de ras | |
| CL2020002919A1 (es) | Inhibidores de mcl-1 | |
| CO2019005287A2 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| MX2024001774A (es) | Compuesto inductor de la degradacion de plk1 novedoso. | |
| CL2024000877A1 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| PE20120998A1 (es) | Metodos para el tratamiento del cancer usando antagonistas de notch | |
| MX2024004216A (es) | Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb. | |
| PE20211266A1 (es) | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas | |
| UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
| MX349188B (es) | Sns - 595 y metodos para utilizar el mismo. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MX369609B (es) | Una composición para usarse en el tratamiento de cáncer deficiente en nmt2. | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
| CO2022007361A2 (es) | Terapia de combinación para el tratamiento de cáncer cerebral | |
| CO2022008817A2 (es) | Macrociclos para uso en el tratamiento de enfermedades | |
| BR112018076639A2 (pt) | quimioterapias de combinação | |
| CL2022001872A1 (es) | Inhibidores de ahr y usos de los mismos |